BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rogocekib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rogocekib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05732103-3062@assetmemo.bio
DTSTAMP:20261121T004552Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rogocekib: Phase 1/2 readout est. (NCT05732103)
DESCRIPTION:Rogocekib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study
  of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk 
 Myelodysplastic Syndromes\nEstimated primary completion: June 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rogocekib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05732103
URL:https://assetmemo.bio/drug/rogocekib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
